Edwards Lifesciences insider plans stock option sale

Edwards Lifesciences Corporation reporting person Daniel J. Lippis filed a notice of proposed sale of common stock in connection with an employee stock option exercise, with broker payment for a cashless exercise expected on 08/11/2026.

Rhea-AI Filing Summary

Edwards Lifesciences Corporation reporting person Daniel J. Lippis filed a notice of proposed sale of common stock in connection with an employee stock option exercise, with broker payment for a cashless exercise expected on 08/11/2026. The notice references trading on the NYSE and includes issuer information for Edwards Lifesciences and Charles Schwab & Co., Inc. as broker.

The filing lists prior sales of Edwards Lifesciences common stock over the past three months by Daniel J. Lippis, including transactions on 05/18/2026, 06/30/2026, and 07/10/2026, each with specified share amounts and dollar values.

Key Figures

Proposed transaction date: 08/11/2026 Prior sale on 05/18/2026: 620 shares; 50,307.00 Prior sale on 06/30/2026: 619 shares; 56,577.00 +2 more

5 metrics

Proposed transaction date 08/11/2026 Planned broker payment for cashless employee stock option exercise

Prior sale on 05/18/2026 620 shares; 50,307.00 Edwards Lifesciences common stock sold by Daniel J. Lippis

Prior sale on 06/30/2026 619 shares; 56,577.00 Edwards Lifesciences common stock sold by Daniel J. Lippis

Prior sale on 07/10/2026 619 shares; 56,762.00 Edwards Lifesciences common stock sold by Daniel J. Lippis

Shares outstanding context figure 576,400,000 Figure listed with Edwards Lifesciences common stock and NYSE

Key Terms

Form 144, Employee Stock Option Exercise, Broker Payment for Cashless Exercise, Securities Sold During The Past 3 Months

4 terms

Form 144 regulatory

"144: Securities Sold During The Past 3 Months"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Employee Stock Option Exercise financial

"Common | 08/11/2026 | Employee Stock Option Exercise - See Remarks"

Broker Payment for Cashless Exercise financial

"1857 | 08/11/2026 | Broker Payment for Cashless Exercise"

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Edwards Lifesciences (EW) disclose in this Form 144 filing?

The filing shows Daniel J. Lippis intends to sell Edwards Lifesciences common stock on 08/11/2026 in connection with an employee stock option exercise, using broker payment for a cashless exercise and referencing trading on the NYSE.

Who is the reporting person in Edwards Lifesciences (EW) Form 144?

The reporting person is Daniel J. Lippis, with an address at ONE EDWARDS WAY, IRVINE, CA 92614. The Form 144 covers his proposed sale of Edwards Lifesciences Corporation common stock related to an employee stock option exercise.

What type of transaction is planned for Edwards Lifesciences (EW) shares?

The planned transaction is tied to an Employee Stock Option Exercise, with the description noting "Broker Payment for Cashless Exercise", and a proposed transaction date of 08/11/2026 for Edwards Lifesciences common stock on the NYSE.

What prior sales are disclosed for Edwards Lifesciences (EW) in the last 3 months?

The filing lists three prior sales by Daniel J. Lippis of Edwards Lifesciences stock: on 05/18/2026 for 620 shares at 50,307.00, on 06/30/2026 for 619 shares at 56,577.00, and on 07/10/2026 for 619 shares at 56,762.00.

Which broker and market are involved in this Edwards Lifesciences (EW) Form 144?

The broker listed is Charles Schwab & Co., Inc., at 3000 Schwab Way, Westlake, TX 76262. The securities are Edwards Lifesciences common stock, and the filing references the NYSE as the market for the planned sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/11/2026 - 04:07 PM Accepted by SEC EDGAR 08/11/2026 - 04:07 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002004380
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Edwards Lifesciences Corp
SEC File Number	001-15525
Address of Issuer	ONE EDWARDS WAY IRVINE CALIFORNIA 92614
Phone	9492502500
Name of Person for Whose Account the Securities are To Be Sold	Lippis Daniel J.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	1857	170900.00	576400000	08/11/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/11/2026	Employee Stock Option Exercise - See Remarks	EDWARDS LIFESCIENCES CORPORATION			1857	08/11/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniel J. Lippis ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	05/18/2026	620	50307.00
Daniel J. Lippis ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	06/30/2026	619	56577.00
Daniel J. Lippis ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	07/10/2026	619	56762.00

144: Remarks and Signature

Remarks	The options on this filing may be sold over various dates.
Date of Notice	08/11/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Daniel J. Lippis
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)